MedPath

FDA Approves Vyjuvek: Breakthrough Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

  • The FDA has granted approval for Vyjuvek, making it the first-ever topical gene therapy authorized for treating dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing severe skin fragility.

  • In pivotal clinical trials, Vyjuvek demonstrated remarkable efficacy with 65% of treated wounds achieving complete healing compared to 26% in the placebo group, offering new hope for DEB patients.

  • Krystal Biotech plans to launch Vyjuvek in Q3 at $24,250 per vial, with typical annual treatment costs estimated at $631,500, addressing a condition that currently burdens US families with monthly wound care costs of up to $10,000.

The US Food and Drug Administration has marked a historic milestone in genetic medicine by approving Krystal Biotech's Vyjuvek (beremagene geperpavec), the first-ever topical gene therapy. This groundbreaking treatment is indicated for patients aged six months and older with dystrophic epidermolysis bullosa (DEB) who carry mutations in the COL7A1 gene.

Understanding DEB and Its Impact

DEB stands as one of the most severe forms of epidermolysis bullosa (EB), often referred to as "the worst disease you have never heard of." This devastating genetic condition causes extreme skin fragility, leading to splitting and blistering from even minimal friction. In severe cases, patients experience internal blistering affecting the mouth, esophagus, gastrointestinal tract, upper airway, and genitourinary system. Until now, treatment options were limited to palliative care.

Revolutionary Treatment Mechanism

Vyjuvek employs an innovative approach using a non-replicating Herpes simplex virus vector to deliver functional copies of the COL7A1 gene directly to wound sites. This genetic payload triggers local production of COL7 molecules, which form crucial anchoring fibrils between the epidermis and dermis layers of the skin. The therapy's unique gel formulation allows for simple weekly application by healthcare professionals, making it accessible even to patients in remote locations.

Clinical Trial Success

The efficacy of Vyjuvek was demonstrated in the GEM-3 clinical trial, involving 31 patients. The study employed a controlled design where two comparable wounds on each patient received either Vyjuvek or placebo. The results were striking: 65% of Vyjuvek-treated wounds achieved complete healing, compared to just 26% in the placebo group.

Market Access and Economic Impact

Krystal Biotech has announced a Q3 launch for Vyjuvek, with each vial priced at $24,250. Based on expected typical usage of 26 vials annually, treatment costs will approximate $631,500 before discounts. While this figure may seem substantial, it addresses a significant unmet need in a condition where families currently face monthly wound care supply costs of up to $10,000. According to DEBRA of America, over 25,000 people in the US live with EB.

Global Development Plans

Looking beyond the US market, Krystal Biotech is actively pursuing global accessibility for Vyjuvek. The company plans to initiate European Union approval procedures in the latter half of this year, with Japanese submission targeted for 2025.

Therapeutic Landscape

The approval of Vyjuvek represents a significant breakthrough in a field where several other companies have faced setbacks. Notable attempts include Shire's (now part of Takeda) development of a recombinant COL7 protein treatment and dermal substitute ABH001, neither of which reached approval. Amicus Therapeutics experienced a Phase 3 trial failure in 2017, while Amryt Pharma's AP101 wound-healing gel continues in development despite an initial FDA rejection.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

ViGeneron's VG901 Receives FDA Rare Pediatric Disease Designation and Advances to Dose Escalation in Phase 1b Trial for Retinitis Pigmentosa

The FDA granted Rare Pediatric Disease Designation to ViGeneron's VG901, a gene therapy for retinitis pigmentosa caused by CNGA1 gene mutations, highlighting the urgent need for new treatments.

FDA Approves First Brain-Delivered Gene Therapy for AADC Deficiency

Eladocagene exuparvovec (Kebilidi) receives accelerated FDA approval as the first gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for aromatic I-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.

FDA Approves Eladocagene Exuparvovec-Tneq (Kebilidi) for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

FDA Approves PTC Therapeutics' Kebilidi, First Direct-to-Brain Gene Therapy

The FDA has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.

FDA Accepts Abeona's Gene Therapy BLA Resubmission for Recessive Dystrophic Epidermolysis Bullosa

The FDA has accepted Abeona Therapeutics' resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) to treat recessive dystrophic epidermolysis bullosa (RDEB).

FDA Approves Elevidys, a Gene Therapy for Duchenne Muscular Dystrophy

The FDA has granted accelerated approval to Elevidys, the first gene therapy for Duchenne muscular dystrophy (DMD) in certain pediatric patients aged 4-5.

FDA Approves First Gene Therapy, Vijuvek, for Rare Skin Disease Epidermolysis Bullosa

The FDA has approved Vijuvek, a topical gene therapy developed by Krystal Biotech, as the first treatment of its kind for epidermolysis bullosa (EB).

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy